Santaris Can't Skirt Isis Suit Over Drug Development Deals

Law360, New York (September 20, 2012, 5:46 PM EDT) -- A California federal judge on Wednesday refused to let Santaris Pharma A/S Corp. off the hook in Isis Pharmaceuticals Inc.'s infringement suit accusing its competitor of leveraging Isis' patented gapmer antisense drug development platform to sign multimillion-dollar deals with industry giants.

U.S. District Judge Barry T. Moskowitz denied Sanrtis’ summary judgment motion without prejudice, saying the company has not convinced him its conduct falls under a federal safe harbor statute.

“The court finds that the facts introduced by Santaris by way of the declaration of one...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.